A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Inclusion criteria

• Over than 18 years old
• Histologically confirmed DLBCL(by central pathology review before enrolment)
• Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
• Measurable disease at time of enrollment (the maximum diameter of cross section ≥1.5cm)
• Life expectancy ≥12 weeks
• Able to receive radiotherapy evaluated by specialist

Exclusion criteria

• Prior radiation therapy within 1 year of infusion
• Pregnant or nursing (lactating) women
• Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion)
• Previous solid tumor within 3 years, previous or concurrent hematological malignancy
• Severe organ dysfunction: left ventricle ejection fraction (LVEF) <40%; DLCO <40%; estimated glomerular filtration rate (eGFR)<30mL/min/1.73 m2; total bilirubin >3 ULN
• HIV positive patients, active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive );
• Other conditions that the investigator may exclude due to risks or other possibilities